# US 2026/0027112 A1 · Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0027112 A1
- Document ID: US20260027112A1
- Status: Published application
- Kind: A1
- Application number: 19/296,221
- Filed: 2025-08-11
- Published: 2026-01-29
- Earliest claimed: 2020-07-10
- Assignees: AstraZeneca AB
- Applicants: AstraZeneca AB
- Inventors: Peter GREASLEY; Christine AHLSTRÖM; Stanko SKRTIC; Robert MENZIES; Anne-Kristina MERCIER; Mikael SUNNÅKER
- Web page: https://patentgrep.com/patent/US20260027112A1

## CPC

- A61K 31/497: containing further heterocyclic rings
- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

A method of reducing total body water in a human patient with chronic kidney disease and in need thereof, the method comprising administering to the patient a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide,
or a pharmaceutically acceptable salt thereof, and dapagliflozin in amounts effective for reducing total body water in the patient.

### Claim 11 (depends on 10)

The method of claim 10, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered once daily in combination with dapagliflozin.

### Claim 12 (depends on 11)

The method of claim 11, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered at a dose of about 5 mg and dapagliflozin is administered at a dose of 10 mg.

### Claim 13 (depends on 11)

The method of claim 11, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered at a dose of about 1.5 mg and dapagliflozin is administered at a dose of 10 mg.

### Claim 14 (depends on 11)

The method of claim 11, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered at a dose of about 0.25 mg and dapagliflozin is administered at a dose of 10 mg.

### Claim 15 (depends on 11)

The method of claim 11, wherein the patient is a chronic kidney disease patient classified as a stage 1-4 patient having an eGFR of 20-60 ml/min/1.73 m2.

### Claim 16 (depends on 15)

The method of claim 15, wherein the patient is a chronic kidney disease patient classified as a stage 3-4 patient.

### Claim 17

A method of reducing risk of fluid retention in a human patient with chronic kidney disease and in need thereof, the method comprising administering to the patient a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide,
or a pharmaceutically acceptable salt thereof, and dapagliflozin in amounts effective for reducing total body water in the patient.

### Claim 18 (depends on 17)

The method of claim 17, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered once daily in combination with dapagliflozin.

### Claim 19 (depends on 18)

The method of claim 18, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered at a dose of about 5 mg and dapagliflozin is administered at a dose of 10 mg.

### Claim 20 (depends on 18)

The method of claim 18, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered at a dose of about 1.5 mg and dapagliflozin is administered at a dose of 10 mg.

### Claim 21 (depends on 18)

The method of claim 18, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered at a dose of about 0.25 mg and dapagliflozin is administered at a dose of 10 mg.

### Claim 22 (depends on 18)

The method of claim 18, wherein the patient is a chronic kidney disease patient classified as a stage 1-4 patient having an eGFR of 20-60 ml/min/1.73 m2.

### Claim 23 (depends on 22)

The method of claim 22, wherein the patient is a chronic kidney disease patient classified as a stage 3-4 patient.

### Claim 24

A method of reducing the likelihood of cardiovascular death in a human patient with chronic kidney disease and in need thereof, the method comprising administering to the patient, a combination of zibotentan, N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3- sulfonamide,
or a pharmaceutically acceptable salt thereof, and dapagliflozin in amounts effective for reducing the incidence of cardiovascular or renal death in the patient.

### Claim 25 (depends on 24)

The method of claim 24, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered once daily in combination with dapagliflozin.

### Claim 26 (depends on 25)

The method of claim 25, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered at a dose of about 5 mg and dapagliflozin is administered at a dose of 10 mg.

### Claim 27 (depends on 25)

The method of claim 25, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered at a dose of about 1.5 mg and dapagliflozin is administered at a dose of 10 mg.

### Claim 28 (depends on 25)

The method of claim 25, wherein zibotentan or a pharmaceutically acceptable salt thereof is administered at a dose of about 0.25 mg and dapagliflozin is administered at a dose of 10 mg.

### Claim 29 (depends on 25)

The method of claim 25, wherein the patient is a chronic kidney disease patient classified as a stage 1-4 patient having an eGFR of 20-60 ml/min/1.73 m2.

### Claim 30 (depends on 29)

The method of claim 29, wherein the patient is a chronic kidney disease patient classified as a stage 3-4 patient.
